A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study
comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE)
recurrence and bleeding in patients with cancer associated VTE (ASTER)